Pulmonx Corporation (LUNG)
| Market Cap | 124.55M +54.1% |
| Revenue (ttm) | 88.78M -3.2% |
| Net Income | -42.55M |
| EPS | -1.01 |
| Shares Out | 43.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 695,065 |
| Open | 2.990 |
| Previous Close | 3.000 |
| Day's Range | 2.780 - 3.040 |
| 52-Week Range | 1.130 - 3.250 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 3.70 (+29.37%) |
| Earnings Date | Oct 27, 2026 |
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult... [Read more]
Financial Performance
In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $3.7, which is an increase of 29.37% from the latest price.
News
Pulmonx Transcript: Stifel 2026 Healthcare Conference 2026
Commercial priorities are rebuilding sales capacity, improving physician training and driving patient throughput at existing accounts; Q3 sales returned to growth in the U.S. and internationally. AeriSeal could expand TAM ~20%, with meaningful non-U.S. revenue expected in 2028.
Pulmonx Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
The turnaround has reduced costs and strengthened liquidity, while Q3 returned to YoY revenue growth as U.S. sales territories are replenished. AeriSeal enrollment is expected to finish in H2 2027, with limited OUS launch planned for 2027.
Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that ma...
Pulmonx price target raised to $4 from $2.50 at Stifel
Stifel raised the firm’s price target on Pulmonx (LUNG) to $4 from $2.50 and keeps a Buy rating on the shares.
Pulmonx Earnings Call Transcript: Q3 2026
Q3 revenue returned to YoY growth in both U.S. and international markets, while adjusted EBITDA loss fell nearly 60%. FY 2026 revenue guidance was reiterated at $90M–$92M, with cost discipline and sales-team productivity supporting the outlook.
Pulmonx Earnings release: Q3 2026
Pulmonx released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Pulmonx Quarterly report: Q3 2026
Pulmonx has published its Q3 2026 quarterly earnings report on October 27, 2026.
Pulmonx reports Q3 EPS (19c), consensus (26c)
Reports Q3 revenue $22.84M, consensus $21.94M. “We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance…
Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.55M
The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross…
Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx Slides: Investor presentation
Pulmonx has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today annou...
Pulmonx management to meet virtually with Lake Street
Virtual Meeting to be held on August 27 hosted by Lake Street.
Pulmonx Transcript: Canaccord Genuity's 46th Annual Growth Conference
Sales leadership and territory coverage have stabilized, with junior reps supporting growth and training. Financial guidance remains strong, with improved margins and reduced costs. AeriSeal is set to expand the addressable market by 20% next year, while China revenue is expected to resume early next year.
Pulmonx reports Q2 EPS (24c), consensus (28c)
Reports Q2 revenue $22.75M, consensus $22.39M. “We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to d...
Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.77M
The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross…
Pulmonx Earnings Call Transcript: Q2 2026
Q2 2026 revenue reached $22.8M, with net loss and adjusted EBITDA loss both significantly reduced year-over-year. Gross margin improved to 78%, and cost alignment initiatives drove a 16% decrease in operating expenses. Full-year guidance is reaffirmed, with China shipments set to resume in early 2027.
Pulmonx Earnings release: Q2 2026
Pulmonx released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Pulmonx Quarterly report: Q2 2026
Pulmonx has published its Q2 2026 quarterly earnings report on July 29, 2026.
Pulmonx Reports Second Quarter 2026 Financial Results
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No shareholder questions were raised, and voting results will be filed with the SEC.
Pulmonx Transcript: Bank of America Global Healthcare Conference 2026
A minimally invasive valve system for severe emphysema has shown strong clinical results and high reimbursement rates, with global reach and a $12 billion addressable market. Recent pipeline expansion and financial restructuring aim to drive renewed growth.